Oncologists across Canada say the rising price of new cancer medicines is leaving some patients to choose between paying huge sums themselves or going without, CBC News reports.
Vancouver man James Howard, who has stage 4 pancreatic cancer, is paying about $63,000 US, or roughly $90,000 Canadian, a month for daraxonrasib. The drug was approved by the US Food and Drug Administration in August but has not been approved in Canada, so he obtains it from the United States.
More than two dozen cancer specialists told the broadcaster that such costs, particularly for treatments not yet approved or publicly funded, are adding pressure on public health care. Doctors quoted in the report described the pricing as driven by greed, while the American manufacturer says the price supports innovation.
Source: CBC News